Navigation Links
Spectros Presents New Clinical Studies Using T-Stat VLS Tissue Oximeter at Anesthesiology 2010
Date:11/2/2010

PORTOLA VALLEY, Calif., Nov. 2, 2010 /PRNewswire/ -- Spectros Corporation presented new clinical results using tissue oxygen saturation with the T-Stat VLS Tissue Oximeter at the San Diego Convention Center during Anesthesiology 2010. This newly released data was presented during poster sessions entitled "Experimental Circulation: Ischemia and Reperfusion" and "Clinical Circulation: Pharmacology/Physiology", held at the American Society of Anesthesiologists (ASA 2010) on October 16, 2010 in San Diego, CA. The studies were both conducted at Loma Linda University Medical Center in Loma Linda, CA.

Loma Linda is just one of the newest locations across the US who is relying on the T-Stat to improve the standard of care and help cut costs. The abstracts, titled, "Regional Tissue Oxygen Saturation in an Animal Model of Global and Regional Oxygen Delivery Insults" and "Esophageal and Buccal Mucosal Oxygen Saturation in Patients Undergoing Cardio-Pulmonary Bypass," help with the ability to assess oxygen delivery to an organ system to provide a more sensitive mode to detect critical disease.

The T-Stat VLS technology can be easily used to monitor the tissue oxygen saturation in numerous locations in the body with a selection of sensors. This concept of monitoring tissue perfusion is not new to the market, however T-Stat's successful and patented VLS white light technology is.

New findings within modern medicine are requiring more modern technologies to assist in tougher diagnosis and more challenging cases.  The T-Stat fills this need with the ability to respond within seconds to changes in tissue perfusion, allowing for real time management of fluid status, cardiac output, and impending shock during surgery, post-operatively, and in the ICU.  "Doctors continue to be enthusiastic about T-Stat's superior performance when compared directly to other tissue oximetry products. We are pleased that T-Stat is gaining momentum in Anesthesiology research and practice," noted Elizabeth van Thillo, Director of Marketing.

Along with the many Anesthesiologists across the US, Spectros is becoming a joining force in improving patient care and making sure that doctors can offer and maintain a safe and successful surgical experience.

About Spectros

Spectros markets and licenses advanced molecular sensing and imaging devices that shed light on ischemia and cancer. The company's champion product, the T-Stat VLS Tissue Oximeter, is the first medical device FDA-approved as sensitive to ischemia, an insufficient supply of oxygen to tissue.  T-Stat is the only commercially-available tissue oximeter that utilizes state-of-the-art multispectral visible light spectroscopy (VLS) technology.  The non-invasive T-Stat VLS system is used clinically to provide a continuous and real-time absolute value, utilizing 260 wavelengths, over the competing NIRS oximeter product lines that only use 2-4.

Spectros also develops molecular diagnostic tools for breast and prostate cancer, currently in phase I/II clinical trials supported by the National Cancer Institute.  Spectros is a venture-supported private concern and markets its products in the U.S. and internationally.

(Note:  Forward-looking statements are intended as a guide only, and do not constitute an offer for investment nor a guarantee of future events or returns.  Certain Spectros applications described above have not been reviewed and approved by the FDA, and are therefore labeled for investigational use only.  T-Stat and Continuum are trademarks of the Spectros Corporation.).

For further information, visit www.spectros.com.


'/>"/>
SOURCE Spectros
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. FDA Grants Market Clearance for the LipiScan(TM) Coronary Imaging System Developed by InfraReDx, Inc. - A Novel Spectroscopy System for the Identification of Lipid Core Containing Plaques of Interest in the Coronary Arteries
2. Bioimpedance Spectroscopy is More Accurate and Reliable Than Other Methods of Subclinical Assessment of Lymphedema in Breast Cancer Patients, According to Paper Published in Journal of Clinical Oncology
3. Spectros Corp. Enters Into Optical Biotechnology Patent Sale Agreement With Philips Electronics N.V.
4. Spectros Presents at the Pediatric Academic Societies (PAS) National Conference 2010
5. ICAP Ocean Tomo Offers IP Portfolio of Near-Infrared Spectroscopy Technology
6. Genaera Corporation Presents Interim Phase 1 Data for Obesity Compound Trodusquemine (MSI-1436) at IBC Conference
7. EntreMed Presents Data for Phase 2 Study of MKC-1 in Metastatic Breast Cancer
8. Pharmasset Presents R7128 Phase 1 Single Ascending Dose Study in Healthy Volunteers
9. Anadys Pharmaceuticals Presents Preclinical Results on ANA598, a Non-Nucleoside Inhibitor of the NS5B Polymerase, at the 14th International Symposium on Hepatitis C Virus and Related Viruses
10. CEL-SCI Presents Data for CEL-1000 as a Vaccine Adjuvant with Recombinant Hepatitis B Virus Protein
11. Ardea Biosciences, Inc. Presents Results of Phase 1 Studies of RDEA806, a Novel NNRTI for HIV, at 47th ICAAC
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/26/2016)... , June 26, 2016 One of Australia,s ... announced the formation of a new biotechnology company, Noxopharm Limited [ABN ... in an IPO and to list on the ASX. ... NOX66, ready to enter a Phase 1 clinical study later this ... to address one of the biggest problems facing cancer patients - ...
(Date:6/26/2016)... June 27, 2016 Jazz Pharmaceuticals plc (Nasdaq: ... under the Hart-Scott-Rodino Antitrust Improvements Act of 1976, as ... Celator Pharmaceuticals, Inc. ("Celator"; Nasdaq: CPXX ) ... Daylight Time). As previously announced on May ... definitive merger agreement under which Jazz Pharmaceuticals has commenced ...
(Date:6/26/2016)... , June 27, 2016  VMS Rehab Systems, Inc. ... will take whatever measures required to build a strong ... which is currently listed on the OTC Markets-pink current ... Chairman and CEO, "We are seeing an anomaly in ... understand, not only by the Company, but shareholders and ...
Breaking Medicine Technology:
(Date:6/25/2016)... ... June 25, 2016 , ... Experts from the American ... Annual Research Meeting June 26-28, 2016, at the Hynes Convention Center in Boston. ... including advance care planning, healthcare costs and patient and family engagement. , AIR ...
(Date:6/25/2016)... ... , ... First Choice Emergency Room , the largest network of independent ... Director of its new Mesquite-Samuell Farm facility. , “We are pleased to announce ... Dr. James M. Muzzarelli, Executive Medical Director of First Choice Emergency Room. , ...
(Date:6/25/2016)... ... June 25, 2016 , ... Conventional wisdom preaches the benefits of moderation, whether ... latter, setting the bar too high can result in disappointment, perhaps even self-loathing. However, ... their goal. , Research from PsychTests.com reveals that behind the tendency ...
(Date:6/24/2016)... PASADENA, CA (PRWEB) , ... June 24, 2016 , ... Marcy was in a crisis. ... he would lash out at his family verbally and physically. , “When something upset him, ... table, he would use it. He would throw rocks at my other children and say ...
(Date:6/24/2016)... San Diego, CA (PRWEB) , ... June 24, 2016 , ... ... up with the American Cancer Society and the Road To Recovery® program to drive ... care to seniors and other adults to ensure the highest quality of life and ...
Breaking Medicine News(10 mins):